| Paper | Authors | Journal | Year | Type |
|---|
| Influence of Albumin Treatment Duration on Outcome of Terlipressin Therapy in Patients With HRS-AKI | Schleicher EM et al. | Liver international : official journal of the International Association for the Study of the Liver | 2026 | Observational Study |
| Chronic Kidney Disease Does Not Influence Response to Terlipressin in Hepatorenal Syndrome-Acute Kidney Injury | Uschner FE et al. | Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association | 2026 | Observational Study |
| Clinical Outcomes of Terlipressin Using Continuous Infusion Versus Bolus in Patients With Acute Variceal Hemorrhage-A Randomized Controlled Trial | Abid S et al. | Journal of clinical gastroenterology | 2026 | Randomized Controlled Trial |
| The relationship between mean arterial pressure and terlipressin in hepatorenal syndrome-acute kidney injury reversal: A post hoc analysis | Cullaro G et al. | Hepatology (Baltimore, Md.) | 2026 | Randomized Controlled Trial |
| Terlipressin for Hepatorenal Syndrome in Patients With Early-Stage Acute-on-Chronic Liver Failure | Rockey DC et al. | Liver international : official journal of the International Association for the Study of the Liver | 2025 | Randomized Controlled Trial |
| Adjunctive terlipressin versus placebo in the treatment of refractory septic shock: a randomized, placebo-controlled trial | Tongyoo S et al. | Critical care (London, England) | 2025 | Randomized Controlled Trial |
| Bradycardia and Other Arrhythmias in Patients With Hepatorenal Syndrome-Acute Kidney Injury Following Terlipressin Treatment: A Pooled Analysis of Three North American Phase III Clinical Studies | Bajaj JS et al. | Alimentary pharmacology & therapeutics | 2025 | Randomized Controlled Trial |
| Predictors of response to terlipressin therapy in hepatorenal syndrome: Metabolomic and proteomic analysis from the CONFIRM trial | Allegretti AS et al. | Hepatology communications | 2025 | Randomized Controlled Trial |
| Addition of midodrine to albumin reduces the incidence of complications of large-volume paracentesis: an RCT comparing midodrine, terlipressin, and albumin | Kulkarni AV et al. | Hepatology international | 2025 | Randomized Controlled Trial |
| Targeted albumin infusions in hospitalized patients with cirrhosis receiving terlipressin: A post-hoc analysis of ATTIRE | Torp N et al. | Annals of hepatology | 2025 | Randomized Controlled Trial |
| Safety and efficacy of continuous infusion terlipressin (BIV201): A phase 2 trial in patients with decompensated cirrhosis and refractory ascites | Bajaj JS et al. | Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society | 2025 | Randomized Controlled Trial |
| The effect of intramyometrial injection of terlipressin versus carbetocin on hemoglobin and blood loss during open myomectomy operations without using haemostatic tourniquets: Double blinded randomized placebo-controlled trial | Elbanna W et al. | European journal of obstetrics, gynecology, and reproductive biology | 2025 | Randomized Controlled Trial |
| The Impact of Intracervical Terlipressin on Intravasation and Venous Embolization During Transcervical Myomectomy and Endometrium Resection: A Randomized Controlled Study | Overdijk LE et al. | Journal of minimally invasive gynecology | 2025 | Randomized Controlled Trial |
| Effect of Continuous Infusion Therapy With Low-dose Terlipressin Combined With Norepinephrine on Hemodynamics, Inflammatory Markers, and Prognosis in Patients With Severe Septic Shock | Li W et al. | Military medicine | 2025 | Randomized Controlled Trial |
| Early Versus Standard Initiation of Terlipressin for Acute Kidney Injury in ACLF: A Randomized Controlled Trial (eTerli Study) | Jindal A et al. | Digestive diseases and sciences | 2024 | Randomized Controlled Trial |
| A Noninferiority Trial Comparing 2 Days vs 5 Days of Terlipressin and Ceftriaxone in Terms of 5-Day Rebleeding for Patients With Acute Gastroesophageal Variceal Hemorrhage | Lo GH et al. | The American journal of gastroenterology | 2024 | Randomized Controlled Trial |
| Continuous home terlipressin infusion increases handgrip strength and reduces ascites-A prospective randomized crossover study | Terbah R et al. | Hepatology (Baltimore, Md.) | 2024 | Randomized Controlled Trial |
| Comparison of 1-day versus 3-day intravenous terlipressin in cirrhosis patients with variceal bleeding: A pilot randomised controlled trial | Vaishnav M et al. | Alimentary pharmacology & therapeutics | 2024 | Randomized Controlled Trial |
| Decreased need for RRT in liver transplant recipients after pretransplant treatment of hepatorenal syndrome-type 1 with terlipressin | Weinberg EM et al. | Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society | 2024 | Randomized Controlled Trial |
| Outcomes of patients with hepatorenal syndrome undergoing liver transplantation in the era of terlipressin | Terbah R et al. | European journal of gastroenterology & hepatology | 2023 | Observational Study |
| Prophylactic terlipressin infusion for severe postreperfusion syndrome in patients undergoing deceased donor liver transplantation: the TIPS-DDLT randomized controlled trial | Zhang L et al. | International journal of surgery (London, England) | 2023 | Randomized Controlled Trial |
| Combination of terlipressin and noradrenaline versus terlipressin in hepatorenal syndrome with early non-response to terlipressin infusion: A randomized trial | Singh V et al. | Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology | 2023 | Randomized Controlled Trial |
| Intraoperative Bleeding Control with Terlipressin in Functional Endoscopic Sinus Surgery | Pavlov VE et al. | The Laryngoscope | 2023 | Randomized Controlled Trial |
| Liver-HERO: hepatorenal syndrome-acute kidney injury (HRS-AKI) treatment with transjugular intrahepatic portosystemic shunt in patients with cirrhosis-a randomized controlled trial | Ripoll C et al. | Trials | 2023 | Randomized Controlled Trial |
| Low-dose continuous terlipressin infusion is effective and safer than intravenous bolus injections in reducing portal pressure and control of acute variceal bleeding | Arora V et al. | Hepatology international | 2023 | Randomized Controlled Trial |
| Terlipressin use and respiratory failure in patients with hepatorenal syndrome type 1 and severe acute-on-chronic liver failure | Wong F et al. | Alimentary pharmacology & therapeutics | 2022 | Randomized Controlled Trial |
| Addition of terlipressin to norepinephrine in septic shock and effect of renal perfusion: a pilot study | Wang J et al. | Renal failure | 2022 | Randomized Controlled Trial |
| RATIONAL FOR CONTINUING TERLIPRESSIN AFTER ENDOSCOPIC VARICEAL LIGATION IN ACUTE VARICEAL HAEMORRHAGE NEEDS FURTHER EVIDENCE: A PILOT STUDY | Poudel RC et al. | Arquivos de gastroenterologia | 2022 | Randomized Controlled Trial |
| Methylene blue versus vasopressin analog for refractory septic shock in the preterm neonate: A randomized controlled trial | Ismail R et al. | Journal of neonatal-perinatal medicine | 2022 | Randomized Controlled Trial |
| Terlipressin and the Treatment of Hepatorenal Syndrome: How the CONFIRM Trial Moves the Story Forward | Belcher JM et al. | American journal of kidney diseases : the official journal of the National Kidney Foundation | 2022 | Randomized Controlled Trial |